Education
About Us
Working with TipRanks
Follow Us
Opthea Limited (CKDXF)
:CKDXF
CKDXF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.29 - $0.57
Previous CloseN/A
Volume9.90K
Average Volume (3M)0.00
Market Cap
$483.22M
Enterprise Value$1.13B
Total Cash (Recent Filing)$172.47M
Total Debt (Recent Filing)$141.65M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding1,367,978,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap2.35
Enterprise Value/Revenue6.21K
Enterprise Value/Gross Profit-9.55K
Enterprise Value/Ebitda-3.97
Forecast
1Y Price Target
$0.03Price Target Upside-93.75% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering0
Opthea News
CKDXF FAQ
What was Opthea Limited’s price range in the past 12 months?
Opthea Limited lowest stock price was $0.29 and its highest was $0.57 in the past 12 months.
What is Opthea Limited’s market cap?
Opthea Limited’s market cap is $483.22M.
When is Opthea Limited’s upcoming earnings report date?
Opthea Limited’s upcoming earnings report date is Feb 26, 2026 which is in 180 days.
How were Opthea Limited’s earnings last quarter?
Opthea Limited released its earnings results on Aug 29, 2025. The company reported -$0.026 earnings per share for the quarter, missing the consensus estimate of -$0.009 by -$0.017.
Is Opthea Limited overvalued?
According to Wall Street analysts Opthea Limited’s price is currently Overvalued.
Does Opthea Limited pay dividends?
Opthea Limited does not currently pay dividends.
What is Opthea Limited’s EPS estimate?
Opthea Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Opthea Limited have?
Opthea Limited has 1,367,978,000 shares outstanding.
What happened to Opthea Limited’s price movement after its last earnings report?
Opthea Limited reported an EPS of -$0.026 in its last earnings report, missing expectations of -$0.009. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Opthea Limited?
Currently, no hedge funds are holding shares in CKDXF
Opthea Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$0.03 (-93.75% Downside)
$0.03 (-93.75% Downside)
Blogger Sentiment
Bullish
CKDXF Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.45%
Trailing 12-Months
Company Description
Opthea Limited
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Technical Analysis
Immutep Ltd
―
Dimerix Limited
―
Race Oncology Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Botanix Pharmaceuticals Limited
―
Ownership Overview
0.02% Insiders
2.50% Mutual Funds
― Other Institutional Investors
96.12% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---